THURSDAY, Oct. 19, 2017 (HealthDay News) -- Women and minorities undergoing percutaneous coronary intervention (PCI) with everolimus-eluting stents have a risk of major adverse cardiac events (MACE) that is similar to that of white men, according to a study published online Oct. 18 in JAMA Cardiology.
Wayne Batchelor, M.D., from the Florida State University College of Medicine in Tallahassee, and colleagues examined one-year outcomes in women and minorities versus white men after PCI with everolimus-eluting stents. The pooled study included 1,635 white men, 1,863 women, and 1,059 minority patients.
The researchers found that compared with white men, women and minorities had a higher prevalence of diabetes, prior stroke, hypertension, renal disease, and congestive heart failure but lower rates of multivessel disease, prior coronary artery bypass graft surgery, prior myocardial infarction (MI), and smoking. Similar unadjusted one-year MACE rates were seen between the groups (white men, 7.6 percent; women, 8.6 percent; and minorities, 9.6 percent); there were no significant differences after risk adjustment. Compared with white men, women and minorities had a higher adjusted risk of death/MI (odds ratios, 1.6 and 1.9, respectively); the adjusted risk of MI was increased among minorities (odds ratio, 2.6). The main driver of these differences was nonstent-related MIs.
"After contemporary everolimus-eluting stent implantation, women and minorities experience a similar risk of one-year MACE but a higher adjusted risk of recurrent ischemic events primarily because of nonstent-related MIs," the authors write.
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
Abstract/Full Text
Editorial (subscription or payment may be required)
